{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:37:22Z","timestamp":1778621842166,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"},{"start":{"date-parts":[[2012,12,13]],"date-time":"2012-12-13T00:00:00Z","timestamp":1355356800000},"content-version":"vor","delay-in-days":134,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Invest"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/bf03261906","type":"journal-article","created":{"date-parts":[[2013,1,4]],"date-time":"2013-01-04T01:18:28Z","timestamp":1357262308000},"page":"e17-e24","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Fidaxomicin for Clostridium difficile-Associated Diarrhoea"],"prefix":"10.1007","volume":"32","author":[{"given":"David Alexander","family":"Sclar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda M.","family":"Robison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ambartsum M.","family":"Oganov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer M.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt A.","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leigh V.","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,13]]},"reference":[{"key":"BF03261906_CR1","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa0910812","volume":"364","author":"T.J. Louie","year":"2011","unstructured":"Louie TJ, Miller MA, Mullane KM, et al. FDX versus vancomycin for C. difficile infection. New Eng J Med 2011; 364: 422\u201331","journal-title":"New Eng J Med"},{"key":"BF03261906_CR2","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1086\/649213","volume":"50","author":"M. Miller","year":"2010","unstructured":"Miller M, Gravel D, Mulvey M, et al. Health care-associated C. difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis 2010; 50: 194\u2013201","journal-title":"Clin Infect Dis"},{"key":"BF03261906_CR3","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1128\/JCM.01484-07","volume":"46","author":"G. Killgore","year":"2008","unstructured":"Killgore G, Thompson A, Johnson S, et al. Comparison of seven techniques for typing international epidemic strains of Clostridium difficile. J Clin Microbiol 2008; 46: 431\u20137","journal-title":"J Clin Microbiol"},{"key":"BF03261906_CR4","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1086\/651706","volume":"31","author":"S.H. Cohen","year":"2010","unstructured":"Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431\u201355","journal-title":"Infect Control Hosp Epidemiol"},{"key":"BF03261906_CR5","unstructured":"Dificid\u00ae [package insert]. San Diego (CA): Optimer Pharmaceuticals, August, 2011"},{"key":"BF03261906_CR6","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1377\/hlthaff.23.1.124","volume":"23","author":"P.J. Neumann","year":"2004","unstructured":"Neumann PJ. Evidence-based and value-based formulary guidelines. Health Aff (Millwood) 2004; 23: 124\u201334","journal-title":"Health Aff (Millwood)"},{"key":"BF03261906_CR7","first-page":"432","volume":"39","author":"W.H. Replogle","year":"2007","unstructured":"Replogle WH, Johnson WD. Interpretation of absolute measures of disease risk in comparative research. Fam Med 2007; 39: 432\u20135","journal-title":"Fam Med"},{"key":"BF03261906_CR8","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I","volume":"17","author":"R.G. Newcombe","year":"1998","unstructured":"Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998; 17: 873\u201390","journal-title":"Stat Med"},{"key":"BF03261906_CR9","unstructured":"U.S. Public Health Service and Health Care Financing Administration. The International Classification of Diseases, 9th Rev., Clinical Modification. Volume 2.(DHHS Pub. No. (PHS) 89\u20131260). Washington, DC: Public Health Service, 1989"},{"key":"BF03261906_CR10","unstructured":"U.S. Nationwide Inpatient Sample (NIS). U.S. Healthcare Cost and Utilization Project (HCUP). Rockville (MD): Agency for Healthcare Research and Quality, 2009"},{"key":"BF03261906_CR11","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1086\/522676","volume":"28","author":"J.A. O\u2019Brien","year":"2007","unstructured":"O\u2019Brien JA, Lahue BJ, Caro JJ, et al. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic conse quences. Infect Control Hosp Epidemiol 2007; 28: 1219\u201327","journal-title":"Infect Control Hosp Epidemiol"},{"key":"BF03261906_CR12","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.jclinepi.2011.08.004","volume":"64","author":"S.M. Chang","year":"2011","unstructured":"Chang SM. The Agency for Healthcare Research and Quality (AHRQ) Effective Health Care (EHC) Program Methods Guide for Comparative Effectiveness Reviews: keeping up-to-date in a rapidly evolving field. J Clin Epidemiol 2011; 64: 1166\u20137","journal-title":"J Clin Epidemiol"},{"key":"BF03261906_CR13","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/cid\/cir404","volume":"53","author":"K.M. Mullane","year":"2011","unstructured":"Mullane KM, Miller MA, Weiss K, et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 2011; 53: 440\u20137","journal-title":"Clin Infect Dis"},{"key":"BF03261906_CR14","first-page":"963","volume":"28","author":"C.M. Kozma","year":"1990","unstructured":"Kozma CM, Reeder CE, Lingle EW. Expanding Medicaid drug formulary coverage. Effects on utilization of related services. Med Care 1990; 28: 963\u201377","journal-title":"Effects on utilization of related services. Med Care"},{"key":"BF03261906_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2165\/00126839-200506030-00003","volume":"6","author":"D.A. Sclar","year":"2005","unstructured":"Sclar DA, Evans MA, Skaer TL, et al. Economic and epidemiologic modeling of full-length antihemophilic factor (recombinant), plasma\/albumin-free method (rAHF-PFM), in previously treated patients with hemophilia A: comparison with B-domain deleted rFVIII (BDDrFVIII), and utility of potential viral transmission reduction due to plasma\/albumin-free status. Drugs R D 2005; 6: 149\u201356","journal-title":"Drugs R D"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03261906.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/BF03261906\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03261906","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03261906.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T16:13:20Z","timestamp":1728922400000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/BF03261906"}},"subtitle":["Epidemiological Method for Estimation of Warranted Price"],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["BF03261906"],"URL":"https:\/\/doi.org\/10.1007\/bf03261906","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8]]},"assertion":[{"value":"13 December 2012","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}